Outset Medical, Inc. (OM) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Outset Medical, Inc. (OM) stock forecast summary
Our AI ranks Outset Medical, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Outset Medical, Inc. is a small-cap company with a market capitalization of $74M. It ranks number 17 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For OM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -32.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OM included.
Follow OM freeOM price chart and AI forecast
How OM ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Outset Medical, Inc. (OM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | OM | Rank |
|---|---|---|
| Market Cap | $74M | 17/30 |
| P/B Ratio | 0.77x | 22/23 |
| EPS | $-2.67 | – |
| Book Value/Share | $5.13 | – |
| Revenue/Share | $6.27 | – |
| FCF/Share | $-2.07 | – |
Profitability & Margins
| Metric | OM | Rank |
|---|---|---|
| ROE | -77.1% | 14/19 |
| ROA | -30.6% | 14/24 |
| ROIC | -33.3% | 18/23 |
| Gross Margin | 41.8% | 21/27 |
| Operating Margin | -56.1% | 19/28 |
| Net Margin | -63.1% | 16/22 |
| EBT Margin | -62.3% | 18/28 |
| Tax Rate | -1.3% | – |
Financial Health
| Metric | OM | Rank |
|---|---|---|
| Current Ratio | 5.19x | 8/30 |
| Quick Ratio | 4.11x | 9/29 |
| D/E Ratio | 1.52x | 6/25 |
| Financial Leverage | 2.52x | 6/25 |
| Interest Coverage | -4.5x | 15/30 |
| Working Capital | $184M | 7/29 |
Cash Flow
| Metric | OM | Rank |
|---|---|---|
| Operating Cash Flow | -$38M | 29/30 |
| Free Cash Flow | -$39M | 13/14 |
| Capital Spending | -$560K | 6/14 |
| FCF/Sales | -33.0% | 8/14 |
| CapEx/Sales | 0.5% | 12/14 |
Operational Efficiency
| Metric | OM | Rank |
|---|---|---|
| Asset Turnover | 0.49x | 14/19 |
| Receivables Turnover | 4.0x | 15/20 |
| Inventory Turnover | 1.4x | 20/27 |
| Fixed Assets Turnover | 31.7x | 8/20 |
| Days Sales Outstanding | 91 days | 6/20 |
| Days Inventory | 252 days | 8/27 |
| Payables Period | 24 days | 21/24 |
| Cash Conversion Cycle | 319 days | 1/19 |
Income Statement
| Metric | OM | Rank |
|---|---|---|
| Total Revenue | $118M | 6/19 |
| Operating Income | -$66M | 29/30 |
| Net Income | -$74M | 24/24 |
| R&D Expense | $22M | 9/28 |
| SG&A Expense | $125M | 9/26 |
| Cost of Goods Sold | $69M | 7/27 |
Dividend & Shareholder Information
| Metric | OM | Rank |
|---|---|---|
| Shares Outstanding | 19M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $228M | 94.1% of assets |
| Cash & Short-term Investments | $35M | 14.5% of assets |
| Accounts Receivable | $29M | 12.1% of assets |
| Inventory | $47M | 19.5% of assets |
| Total Liabilities | $146M | 60.3% of assets |
| Short-term Debt | $39M | 16.3% of assets |
OM quarterly financials and insider trading
Outset Medical, Inc. (OM) industry peers
Companies classified under the same SEC industry code as Outset Medical, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| OM Outset Medical, Inc. | ▲ | $74M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| VASO Vaso Corp | ▲ | $51M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▼ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where OM sits on the market map
Outset Medical, Inc. (OM) stock news
Loading...
Outset Medical, Inc. (OM) stock forecast FAQ
What is the Outset Medical, Inc. (OM) stock forecast?
Our AI ranks Outset Medical, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Outset Medical, Inc. stock predictions?
For OM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -32.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Outset Medical, Inc. forecasts updated?
Outset Medical, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Outset Medical, Inc.'s industry peers?
32 issuers in our coverage, OM included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.